What Пуринол Treats: Main Uses and Benefits

The medication is commonly used for managing conditions associated with high levels of uric acid. This application relates to several potential therapeutic supports for patients dealing with gout and certain kidney stones, including conditions characterized by periods of heightened symptoms and those involving recurrent or episodic manifestations.

---

Easing Episodic Symptom Discomfort

Пуринол is commonly used to address groups of symptoms that may appear suddenly or intensify, such as the acute episodes of discomfort and swelling associated with gout. It is applied across domains where additional symptomatic support is needed, and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relevant for Temporary Physiological Imbalance

---

Supporting Management and Comfort

This medication is relevant for conditions characterized by episodic or fluctuating symptom patterns, particularly those marked by periods of increased physiological stress. Пуринол is considered relevant in clinical settings by helping to ease the overall burden of symptoms linked to hyperuricemia. It contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus overview on Allopurinol

Пуринол (allopurinol) is primarily indicated for adults with chronic gout or hyperuricemia (excess uric acid in the blood) and is also used in adults and children to manage high uric acid levels caused by certain cancer therapies or to prevent specific types of kidney stones.

However, it is not suitable for everyone. This medication is contraindicated and should not be used if you have a known hypersensitivity or allergic reaction to allopurinol or any of its ingredients.

---

Caution is required for certain individuals, who must consult their doctor:

Special Consideration	Reason for Caution
Impaired Kidney or Liver Function	Dose adjustment is often necessary, as the drug is primarily eliminated by the kidneys.
Acute Gout Attack	Should not be started during an active, initial gout flare.
Specific Ethnic Backgrounds	Patients of Han Chinese, Korean, or Thai descent have a higher risk of severe hypersensitivity reactions due to a genetic marker (*HLA-B58:01 allele**). Pre-screening may be considered.
Pregnancy and Breastfeeding	Use only if the potential benefits outweigh the risks; generally avoided during breastfeeding.

Additionally, caution is needed when taking other medications, such as azathioprine and mercaptopurine, as the dose of these drugs usually needs to be significantly reduced when taken concurrently with Пуринол.

Interactions with other medicines and products

Пуринол (Allopurinol) is officially documented to interact with several medicinal products, primarily through its ability to inhibit the xanthine oxidase enzyme. These interactions result in specific regulatory constraints that govern co-administration.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with Azathioprine or Mercaptopurine requires a mandatory dose reduction of the thiopurine drug. This restriction is due to inhibition of enzymatic oxidation, which leads to markedly increased systemic exposure of the thiopurines. Similarly, metabolism of Theophylline is documented to be decreased, resulting in a rise in its plasma concentration.

Official regulatory restrictions apply to combinations that augment risk. Co-administration with Thiazide Diuretics or ACE Inhibitors is officially linked to an increased risk of serious hypersensitivity reactions. The interaction with Coumarin Anticoagulants requires mandatory monitoring of prothrombin time due to documented potentiation of the anticoagulant effect.

Administration and Population Constraints

To prevent reduced Allopurinol absorption, a time separation of at least 3 hours is required when co-administering with Aluminum Hydroxide antacids. A critical, population-specific constraint is the increased risk of severe skin reactions in carriers of the *HLA-B58:01 allele, resulting in a regulatory restriction on use in these patients. The use of Pegloticase is a formally restricted combination**, requiring Allopurinol discontinuation during treatment.

How Пуринол Works: The Mechanism of Action

The pharmacological effect of Пуринол (Allopurinol) is rooted in its action as an enzyme inhibitor, which modulates the final steps of the body's purine catabolism pathway.

---

Targeted Enzyme Inhibition (Xanthine Oxidase)

The mechanism begins with the parent drug, Allopurinol, and its active metabolite, Oxypurinol, which directly target the enzyme Xanthine Oxidase (XO). This enzyme is crucial for synthesizing Uric Acid. The drug acts as a molecular block, preventing the XO enzyme from carrying out the oxidation of purine precursors. This enzyme inhibition is the foundational step that dictates the drug's downstream effects and its required chronicity of use.

---

Shifting the Systemic Purine Balance

By blocking the pathway at Xanthine Oxidase, the drug interrupts the production of the end-product, Uric Acid. Instead, the system accumulates its precursors, Hypoxanthine and Xanthine, which are readily soluble. This systemic shift in metabolism results in a reduction in the rate of Uric Acid production, thereby achieving a measurable and sustained decrease in the circulating Urate concentration throughout the body.

How to Use Пуринол

Пуринол (Allopurinol) is a medicine generally administered via the oral route as a tablet intended for long-term chronic therapy to manage conditions characterized by excess uric acid. In specific clinical scenarios, such as when oral administration is not feasible, an intravenous (IV) preparation may also be used in a controlled setting.

The therapy protocol requires initiating treatment at a low dose, typically 100 mg once daily for adults, followed by a gradual titration to establish the effective maintenance level. The maintenance dose can range from 200 mg to 900 mg per day. Doses exceeding 300 mg are generally administered in divided doses to enhance patient tolerability. The oral tablet must be taken with or immediately after food to minimize gastrointestinal upset.

Proper use also requires maintaining adequate fluid intake, often specified as a daily urinary output of at least two liters. A crucial instruction involves dose adjustment for specific populations, particularly those with renal impairment, where a significant reduction in dosage or frequency (e.g., every other day) is required. The drug is intended for sustained, long-term use and not for episodic or short courses of treatment.

Research Evidence / Overview of Studies for Пуринол (Allopurinol)

Evidence for Use in Chronic Gout Management

The research base for the chronic management of gout has been explored through Randomized Controlled Trials (RCTs) and systematic reviews. These trials monitored serum urate concentration (SUA), which is the level of uric acid in the blood. Studies were designed to compare the active substance against a placebo or against other urate-lowering medications.

In these trials, researchers tracked whether the active substance was observed to maintain SUA levels below a specific target concentration and explored changes in the frequency of acute gout attacks (flares) reported by participants. Findings from these comparisons indicated patterns of reduced SUA measurements in the groups receiving the active substance compared to placebo. However, evidence regarding the long-term changes in flare frequency varied across different studies.

Evidence for Use in Preventing Acute Kidney Issues During Cancer Therapy

The evidence base for this context consists of short-term trials and clinical data, with research focusing on the period immediately surrounding the start of chemotherapy. This use is relevant where a rapid increase in uric acid can occur, as in Tumor Lysis Syndrome (TLS). Researchers monitored participants for extreme elevations in uric acid and the subsequent development of Acute Kidney Injury (AKI). The data show patterns related to changes in serum uric acid measurements during this short-term period of physiological strain.

What is Still Uncertain About Пуринол Research

One key limitation is that many of the RCTs are short-term, offering limited information for long-term outcomes such as sustained flare prevention and disease progression. Research has explored whether patterns are observed in long-term clinical events, including those related to cardiovascular health. However, data for certain groups, such as those with severe kidney impairment, often remain insufficient for drawing broad conclusions, and evidence quality varies across studies.

Common questions about Пуринол (FAQ)

Q: How long does it take for Пуринол to start working and lower uric acid?

A: Product information suggests that the initial effect of lowering uric acid may be noticeable within the first few days of beginning therapy. However, achieving a sustained, target level of serum uric acid concentration (the amount of uric acid in the blood) usually requires one to three weeks of consistent treatment. The time frame may vary for each person.

Q: What should I do if I miss a dose of Пуринол?

A: Regulatory guidance suggests that if a dose is missed, it can generally be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the advice is to skip the missed dose and continue with the regular schedule. Official prescribing information advises against taking two doses together to compensate for a forgotten dose.

Q: Can I take Пуринол for an acute gout attack?

A: Official product labeling advises that starting this medication during an acute gout flare is generally discouraged, as there is a risk of potentially triggering additional attacks. If a gout flare develops while a person is already on the medication, regulatory information indicates that treatment is often continued, and the flare is managed with other appropriate therapy.

Q: What happens if I suddenly stop taking my Allopurinol?

A: Official information suggests this medication is intended for continuous, long-term management of high uric acid levels. Stopping treatment suddenly is associated with an increased risk of gout symptoms worsening and may result in an increase in uric acid levels. Any decision regarding discontinuation or dose adjustment should be discussed with a healthcare provider.

Q: Is it possible to overdose on Allopurinol? What are the signs?

A: Yes, it is possible to overdose on Allopurinol. Symptoms reported following massive oral ingestion include nausea, vomiting, diarrhea, and dizziness. The labeling emphasizes that immediate medical attention should be sought if an overdose is suspected.

Q: How should I dispose of unused or expired Пуринол tablets?

A: The official guidance advises against discarding unused or expired tablets via wastewater or regular household trash. Instead, disposal programs recommend utilizing a formal medicine take-back program or an authorized local collection site. If a take-back program is unavailable, certain government guidelines provide specific instructions for secure household disposal, such as mixing the product with an undesirable substance and placing it in a sealed container before discarding.

How to Store and Dispose of Allopurinol (Пуринол)

Storage Requirement	Conditions Mandated by Regulatory Labeling
Temperature	Store at Controlled Room Temperature (20 C to 25 C), with excursions permitted up to 30 C.
Container & Protection	Keep the product in the original container and maintain it tightly closed. The medicine must be protected from light and moisture.
Child Safety	Store the tablets out of the sight and reach of children.
IV Solution Stability	Reconstituted or diluted Allopurinol IV solution must not be refrigerated and must be used within 10 hours of preparation.

Disposal Instructions

Unused or expired Allopurinol must not be disposed of via wastewater or standard household trash. Disposal must be carried out according to local regulations and official collection programs. Any unused portions of the IV product must be discarded.